amprenavir + lamivudine + zidovudine

This is a **three-drug combination** used in antiretroviral therapy for HIV-1 infection, composed of the protease inhibitor amprenavir and two nucleoside reverse transcriptase inhibitors (NRTIs), lamivudine and zidovudine. - **Amprenavir** inhibits HIV-1 protease, preventing the cleavage of viral polyproteins necessary for the production of mature, infectious viral particles. - **Lamivudine** and **zidovudine** are both NRTIs that inhibit reverse transcriptase, blocking the transcription of viral RNA into DNA. The combination has demonstrated **potent and durable antiviral activity**, with a significantly higher rate of plasma HIV-1 RNA suppression compared to lamivudine and zidovudine alone in treatment-naive adults[1][2]. This regimen was historically used in patients initiating HIV therapy and contributed to the early successes of combined antiretroviral therapy (cART).